Susanne Schmaus

Title: Susanne Schmaus: Innovator in Tumor Treatment

Introduction

Susanne Schmaus is a prominent inventor based in Munich, Germany. She has made significant contributions to the field of medical science, particularly in the treatment of tumors. Her innovative approach focuses on the use of oligonucleotides, which are short strands of nucleic acids that can interfere with gene expression.

Latest Patents

Susanne Schmaus holds a patent for a method titled "Dosage of oligonucleotides suitable for the treatment of tumors." This patent describes a method for preventing and/or treating tumors by intravenously administering an antisense oligonucleotide. The treatment involves administering an amount between about 400 to about 800 mg/m/treatment cycle. The antisense oligonucleotide comprises 8 to 30 nucleotide building blocks, which hybridize with mRNA of TGF-beta-2, -1, and/or -3 for the preparation of a pharmaceutical composition.

Career Highlights

Throughout her career, Susanne has worked with notable companies in the pharmaceutical industry, including Antisense Pharma GmbH and Autotelic, LLC. Her work has been instrumental in advancing therapeutic strategies for cancer treatment.

Collaborations

Susanne has collaborated with esteemed colleagues such as Karl-Hermann Schlingensiepen and Hubert Heinrichs. These partnerships have contributed to her research and the development of innovative treatment methods.

Conclusion

Susanne Schmaus is a trailblazer in the field of tumor treatment, with her patent showcasing her commitment to advancing medical science. Her work continues to inspire future innovations in cancer therapy.